Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04296916
Other study ID # 2020KYPJ026
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 17, 2020
Est. completion date October 2024

Study information

Verified date May 2022
Source Sun Yat-sen University
Contact Xiulan Zhang, MD, PhD
Phone +86 13570166308
Email zhangxl2@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Currently, whether and when intraocular pressure (IOP) lowering medication should be used in glaucoma suspects with high myopia (HM) is still a dilemma. Randomized trials are required to evaluate whether IOP lowering influences the incidence of glaucoma suspect progression in HM eyes.


Description:

HM is associated with increased prevalence of glaucoma. However, accurate diagnosis of glaucoma in HM is a challenge. More and more viewpoints had been raised that HM eyes with optic disc head damage or/and visual field (VF) defects should been classified as glaucoma suspects. IOP is the only modifiable parameter in glaucoma and glaucoma suspect patients. However, the decision to begin treatment to lower IOP in the glaucoma suspect patient is complex, especially for glaucoma suspects with HM. There are lack of guideline and consensus of treatment choices. Therefore, it is necessary to investigate the effect of medically IOP lowering on the progression of glaucoma suspects with HM.


Recruitment information / eligibility

Status Recruiting
Enrollment 264
Est. completion date October 2024
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria: 1. Aged between 35 and 65 years. 2. Diagnosed with high myopia (spherical equivalent = -8.00 diopters or axial length = 26.5 mm). 3. Diagnosed with glaucoma suspect, which cannot be explained by myopic macular changes, or other retinal and neurologic condition. 4. IOP = 12 mmHg and = 24mmHg on at least 2 visits, as measured by Goldmann applanation tonometry. 5. An open anterior chamber angle as based upon gonioscopy. 6. Best corrected visual acuity (BCVA) = 6/12. Exclusion Criteria: 1. Allergy to prostaglandins. 2. Advanced VF loss (MD worse than 16 dB) or a threat to fixation (sensitivity 10 dB or worse affecting either or both test points closest to the point of fixation in the upper hemifield and at either or both of the corresponding test points in the lower hemifield) in either eye. 3. Previous IOP-lowering surgery in the study eye (i.e. trabeculectomy, Ahmed glaucoma valve implantation, any laser trabeculoplasty). 4. Previous cataract surgery in the study eye. 5. Previous corneal refractive surgery in the study eye. 6. Clinically significant or progressive retinal disease such as proliferative diabetic retinopathy, retinal detachment, central retinal vein occlusion, or retinitis pigmentosa in the study eye. 7. Chronic, recurrent or severe inflammatory eye disease in the study eye (from screening), such as chronic or recurrent uveitis. 8. Obvious corneal and iris lesions, or severe cataracts interfering with fundus examinations, or monophtalmia. 9. Need for ocular surgery/laser or anticipated need for cataract surgery that would influence the ophthalmological parameters measured in this study during the study period. 10. Other serious systemic diseases (i.e. hypertension, heart disease, diabetes, or rheumatic immune system diseases). 11. Pregnant or nursing women.

Study Design


Intervention

Drug:
IOP lowering eye drops
Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops.

Locations

Country Name City State
China Zhongshan Ophthalmic Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

References & Publications (3)

Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald — View Citation

Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999 Nov;106(11):2144-53. — View Citation

Leske MC, Hyman L, Hussein M, Heijl A, Bengtsson B. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure r — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The number of subjects whose visual filed progressed during the follow up 36 months
Secondary The number of subjects whose optic nerve head morphology including the retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) changed during the follow up 36 months
Secondary The number of subjects whose myopic maculopathy progressed during the follow up 36 months
Secondary The number of subjects whose visual function and quality of life changed during follow up 36 months
See also
  Status Clinical Trial Phase
Completed NCT01658761 - Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes N/A
Enrolling by invitation NCT03666052 - Shanghai Child and Adolescent Large-scale Eye Study -High Myopia Registration
Completed NCT03294967 - Effect of Caffeine on Ocular Circulation in High Myopes N/A
Not yet recruiting NCT05550740 - Repeated Low-Level Red-Light Therapy for Shortening Axial Length N/A
Not yet recruiting NCT05095194 - Influence of Capsular Tension Ring on IOL-capsular Complex After Cataract Surgery in Patients With High Myopia: a Clinical Observation Based on SS-OCT N/A
Suspended NCT02915133 - The Relationship Between Structure and Visual Function in Myopia Foveoschisis
Not yet recruiting NCT05533450 - A Study on the Efficacy and Safety of Multi-focal Scleral Contact Lens N/A
Not yet recruiting NCT05042856 - To Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract Patients N/A
Completed NCT03266354 - Changes of the Corneal Endothelial Cell Count After Artisan Phakic Intraocular Lens Implantation
Recruiting NCT05201677 - Improved Operation of Low Intraocular Pressure in Phacoemulsification for Patients With High Myopia Complicated With Cataract N/A
Completed NCT02169635 - Macular Buckle With Three-armed Silicone N/A
Recruiting NCT03533647 - Development and Pathological Changes of High Myopia Among Children and Adolescents in China
Completed NCT06204211 - Genetic Research on High Myopic Individuals in Northern China
Active, not recruiting NCT05691296 - The Monitoring and Intervention of Refractive Changes in Children and Teenagers in Tianjin N/A
Completed NCT03202485 - Comparison Between TICL and ICL+AK for High Myopic Astigmatism N/A
Not yet recruiting NCT05768152 - Repeated Low-Level Red-Light Therapy Shortens Axial Length N/A
Completed NCT00564213 - Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds Phase 4
Active, not recruiting NCT05803174 - Screening and Identification of Biomarkers for High Myopia by a Rapid Method
Completed NCT03174639 - High Myopia Macular Hole and Retinal Detachment Treated With Double ILM Flaps N/A
Not yet recruiting NCT06264830 - 3D Visualization System in Highly Myopic Cataract Operation N/A